Haim Belmaker

Prof. Haim Belmaker

orcid

Research Focus & Metrics

Academic Career Length

42Years (1985-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 January 2008 in New England Journal of Medicine
Verified
Journal Article
Closed access
HBHaim Belmaker
Haim Belmaker
GAGalila Agam
Galila Agam
This review of major depressive disorder is a comprehensive account of the genetic, biochemical, and neurophysiological changes that have been implicated in the disorder. No single mechanism can account for all the clinical variations in this condition. The monoamine oxidase theory can explain many of the actions of antidepressants, but genetic factors, stress, and psychosocial factors also play a part in depression.

1 June 2006 in American Journal of Psychiatry
Verified
Journal Article
Closed access
PDF file
HNHanah Nemets
Hanah Nemets
BNBoris Nemets
Boris Nemets
AAAlan Apter
Alan Apter
ZBZiva Bracha
Ziva Bracha
HBHaim Belmaker
Haim Belmaker

5 June 2015 in International Journal of Bipolar Disorders
Verified
Journal Article
Open access
PDF file
Abed N. AzabAbed N. Azab
Abed N. Azab
ASAlla Shnaider
Alla Shnaider
YOYamima Osher
Yamima Osher
DWDana Wang
Dana Wang
YBYuly Bersudsky
Yuly Bersudsky
HBHaim Belmaker
Haim Belmaker
Reports of toxic effects on the kidney of lithium treatment emerged very soon after lithium therapy was introduced. Lithium-induced nephrogenic diabetes insipidus is usually self-limiting or not clinically dangerous. Some reports of irreversible chronic kidney disease and renal failure were difficult to attribute to lithium treatment since chronic kidney disease and renal failure exist in the population at large. In recent years, large-scale epidemiological studies have convincingly shown that lithium treatment elevates the risk of chronic kidney disease and renal failure. Most patients do not experience renal side effects. The most common side effect of polyuria only weakly predicts increasing creatinine or reduced kidney function. Among those patients who do experience decrease in creatinine clearance, some may require continuation of lithium treatment even as their creatinine increases. Other patients may be able to switch to a different mood stabilizer medication, but kidney function may continue to deteriorate even after lithium cessation. Most, but not all, evidence today recommends using a lower lithium plasma level target for long-term maintenance and thereby reducing risks of severe nephrotoxicity.

1 August 2009 in Journal of Child and Adolescent Psychopharmacology
Verified
Journal Article
Closed access
GMGal Meiri
Gal Meiri
YBYoav Bichovsky
Yoav Bichovsky
HBHaim Belmaker
Haim Belmaker
The purpose of this study was to determine the efficacy and safety of omega-3 fatty acids for children with autistic spectrum disorder (ASD). This was an open-label pilot study. Ten children aged 4-7 years old with ASD according to the Diagnostic and Statistical Manual of Mental Disorders, 4(th) edition (DSM-IV), were given 1 gram daily of omega-3 fatty acids for 12 weeks. The main outcome measure used was the Autism Treatment Evaluation Checklist (ATEC). These data were collected between July, 2006, and June, 2007. Of the 9 subjects who completed the study, 8 showed improvement of about 33% on the Autism Treatment Evaluation Checklist (ATEC). None worsened and no side effects were reported. Omega-3 fatty acids appear to be safe and might be helpful for children suffering from ASD. Further study is needed with a larger number of children in a double-blind design and with various doses of omega-3 fatty acids.

1 September 2005 in Progress in Neuro-Psychopharmacology and Biological Psychiatry
Verified
Journal Article
Closed access
JLJoseph Levine
Joseph Levine
BSBen-Ami Sela
Ben-Ami Sela
YOYamima Osher
Yamima Osher
HBHaim Belmaker
Haim Belmaker

1 August 2008 in CNS Spectrums
Verified
Journal Article
Closed access
PDF file
HBHaim Belmaker
Haim Belmaker
Along with the development of selective sertonin reuptake inhibitors there has been a tremendous widening of the definition of depression and an impressive decrease in the placebodrug difference in controlled studies. In the early 1960s, about one third of depressed patients improved with placebo and two thirds with active compounds. Current controlled studies suggest that the situation has certainly not improved. The Sequenced Treatment Alternatives to Relieve Depression Study found that response rates to new compounds after the failure of the first antidepressant are low. The monoamine hypothesis of depression was formulated in the mid 1960s based on the antidepressant efficacy of the monoamine reuptake inhibitors, monoamine oxidase inhibitors, and the depressogenic effects of reserpine as a monoamine depleter. However, no monoamine-related finding has been found that is diagnostic for depression. A second major hypothesis regarding depression has been the stress cortisol hypothesis. However, blood cortisol levels are not diagnostic of depression. Psychiatric clinicians are convinced that there are patients for whom antidepressants have made the difference between life and death. However, physicians may generalize unjustifiably based on single dramatic cases to a much larger diagnostic group. Perhaps there are many causes of different types of human sadness, and perhaps only some of these involve mechanisms related to monoamines. Thus, perhaps only some kinds of depression are responsive to monoamine affecting antidepressants.